BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 32027018)

  • 1. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
    Quandt Z; Young A; Anderson M
    Clin Exp Immunol; 2020 May; 200(2):131-140. PubMed ID: 32027018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
    Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
    Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
    Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
    Chow LQ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Checkpoint Blockade Therapy in Lymphoma.
    Kuzume A; Chi S; Yamauchi N; Minami Y
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
    Deligiorgi MV; Panayiotidis MI; Trafalis DT
    Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
    Park JA; Cheung NV
    Cancer Treat Rev; 2017 Jul; 58():22-33. PubMed ID: 28622628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint inhibitors in AML: are we there yet?
    Ghosh A; Barba P; Perales MA
    Br J Haematol; 2020 Jan; 188(1):159-167. PubMed ID: 31808941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.